An Updated Systematic Review and Meta-analysis of the Short- and Long-term Outcomes of Percutaneous Coronary Intervention for Patients with Severe Left Ventricular Systolic Dysfunction
Main Article Content
Abstract
Background: Coronary artery disease (CAD) is the most common cause of left ventricular dysfunction (LVD). Conflicting evidence exists with regards to available treatments and patient prognosis. Revascularization may improve ventricular function while coronary artery bypass surgery (CABG) has significantly improved survival. The effectiveness of percutaneous coronary intervention (PCI) has also not been thoroughly investigated to date.
Objectives: To ascertain the in-hospital and long-term (≥1 year) outcomes of CAD patients with LV systolic dysfunction (ejection fraction ≤40%) after PCI according to a meta-analysis.
Methods: A systematic literature search and a series of random-effect meta-analyses were conducted to evaluate the short- and long-term outcomes of PCI of the selected studies. Single-center studies and those that did not report evidence on long-term mortality were excluded in the analysis. All statistical tests were performed with 95% confidence intervals. A p-value of less than 0.05 was considered statistically significant.
Results: A total of 25 studies involving 5,471 patients (78% males, average age 65.1 years) were identified. The average follow-up duration was approximately 27 months. The majority of patients had multi-vessel disease (68%), hypertension (66%), hypercholesterolemia (59%), and prior myocardial infarction (MI) (58%). The meta-analysis showed that the in-hospital occurrence of major adverse cardiac events (MACE), deaths, MI, and repeat revascularization (RR) after PCI were controlled at 4%, 2%, 2%, and 1%, respectively. The pooled estimates for long-term outcome were 40% MACE, 20% deaths, 4% MI, and 21% RR. There was no significant difference in mortality risk when PCI was compared with CABG (p=0.71).
Conclusion: PCI carries acceptable short- and long-term outcomes for CAD patients with LV systolic dysfunction.
Downloads
Article Details
Copyright (c) 2018 Abudukeremu N, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Toda K, Mackenzie K, Mehra MR, DiCorte CJ, Davis JE, et al. (2002) Revascularization in severe ventricular dysfunction (15% https://goo.gl/iSsxSR
Appoo J, Norris C, Merali S, Graham MM, Koshal A, et al. (2004) Long-term outcome of isolated coronary artery bypass surgery in patients with severe left ventricular dysfunction. Circulation 110: II13eII17.
Sedlis SP, Ramanathan KB, Morrison DA, Sethi G, Sacks J, et al. (2004) Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions,unstable angina pectoris, and risk factors for adverse outcomes with bypass (the AWESOME Randomized Trial and Registry). Am J Cardiol 94: 118e120. Link: https://goo.gl/6Hof7r
Buszman P, Szkrobka I, Gruszka A, Parma R, Tendera Z, et al. (2007) Tendera M.Comparison of effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in patients with ischemic cardiomyopathy. Am J Cardiol 99: 36e41. Link: https://goo.gl/AzaWFN
Lindsay J Jr, Grasa G, Pinnow EE, Plude G, Pichard AD (1999) Procedural results of coronary angioplasty but not late mortality have improved in patients with depressed left ventricular function. Clin Cardiol 22: 533–536. Link: https://goo.gl/aouyQh
Keelan PC, Johnston JM, Koru-Sengul T, Detre KM, Williams DO, et al. (2003) Comparison of in-hospital and one-year outcomes in patients with left ventricular ejection fractions or = 50%having percutaneous coronary revascularization. Am J Cardiol 91: 1168–1172. Link: https://goo.gl/Umgg6j
Wallace TW, Berger JS, Wang A, Velazquez EJ, Brown DL (2009) Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention. Am J Cardiol 103: 355–360. Link: https://goo.gl/EuY159
Goto M, Kohsaka S, Aoki N, Lee VV, Elayda MA, et al. (2008) Risk stratification after successful coronary revascularization. Cardiovasc Revasc Med 9: 132–139.
Biondi Zoccai G, Moretti C, Abbate A, Lipinski MJ, De Luca G, et al. (2007) Percutaneous coronary stenting in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. EuroIntervention 3: 409–415.
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, et al. (2011) Coronary-artery bypass surgery in patients with left ventricular dysfunction.N Engl J Med 364: 1607–1616. Link: https://goo.gl/Pc5H7L
Kunadian V, Pugh A, Zaman AG, Qiu W (2012) Percutaneous coronary intervention among patients with left ventricular systolic dysfunction: a review and meta-analysis of 19 clinical studies. Coron Artery Dis 23: 469-79. Link: https://goo.gl/Arb8w7
Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, et al. (2010) Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery(SYNTAX) trial. Circulation 121: 2645–2653.
Gioia G, Matthai W, Gillin K, Dralle J, Benassi A, et al. (2007) Revascularization in severe left ventricular dysfunction: outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting.Catheter Cardiovasc Interv 70:26–33.
Cleland JG, Calvert M, Freemantle N, Arrow Y, Ball SG, et al. (2011) The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail 13: 227–233. Link: https://goo.gl/MCsrEg
Ahn JM, Park D, Park GM, Kim YG, Choi HO, et al. (2011) Comparison of drug-eluting stents vs. coronary artery bypass grafting for patients with multivessel disease ans severely compromised ventricular dysfunction. J Am Coll Cardiol 2010; 56:B76.Heart Fail 13: 773–784.
Wells G, Shea B, O'Connell D, Petersen J, Welch V, et al. (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. Available: Link: https://goo.gl/DEVLUT
Aslam F, Blankenship JC (2005) Coronary artery stenting in patients with severe left ventricular dysfunction. J Invasive Cardiol 17: 656–658.
Alidoosti M, Salarifar M, Zeinali AM, Kassaian SE, Dehkordi MR, et al. (2008) Short- and long-term outcomes of percutaneous coronary intervention in patients with low, intermediate and high ejection fraction. Cardiovasc J Afr 19: 17–21. Link: https://goo.gl/3xqyqL
Sheiban I, Moretti C, Biondi Zoccai G, Rosano GM, Sciuto F, et al. (2007) Short- and long-term outcomes of percutaneous coronary interventions in patients with severe left ventricular dysfunction. EuroIntervention 3: 359–364.ss
Nagendran J, Norris CM, Graham MM, Ross DB, Macarthur RG, et al. (2013) APPROACH Investigators. Coronary revascularization for patients with severe left ventricular dysfunction. Ann Thorac Surg 96: 2038-44.
Sardi GL, Gaglia MA Jr, Maluenda G, Torguson R, Laynez-Carnicero A, et al. (2011) Outcome of percutaneous coronary intervention utilizing drug-eluting stents in patients with reduced left ventricular ejection fraction. Am J Cardiol. 109: 344-51. Link: https://goo.gl/AvBDQ4
Briguori C, Aranzulla TC, Airoldi F, Cosgrave J, Tavano D, et al. (2009) Stent implantation in patients with severe left ventricular systolic dysfunction. Int J Cardiol 135: 376–384.
Di Sciascio G, Patti G, D’Ambrosio A, Nusca A (2003) Coronary stenting in patients with depressed left ventricular function: acute and long-term results in a selected population. Catheter Cardiovasc Interv 59: 429–433. Link: https://goo.gl/3PxSCB
Biondi-Zoccai G, Sheiban I, Moretti C, Palmerini T, Marzocchi A, et al. (2011) Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients. Clin Res Cardiol 100: 403–411. Link: https://goo.gl/wcGXZs
Daneault B, Généreux P, Kirtane AJ, Witzenbichler B, Guagliumi G, et al. (2012) Comparison of Three-year outcomes after primary percutaneous coronary intervention in patients with left ventricular ejection fraction <40% versus ≥40% (from the HORIZONS-AMI trial). Am J Cardiol 111: 12-20. Link: https://goo.gl/Dc6vus
Perera D, Stables R, Clayton T, De Silva K, Lumley M, et al. (2013) BCIS-1 Investigators. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention. Circulation 127: 207-12. Link: https://goo.gl/nsL1SU
Bollati M, Gerasimou A, Sillano D, Biondi-Zoccai G, Garrone P, et al. (2010) Results of percutaneous drug-eluting stent implantation for unprotected left main coronary disease according to left ventricular systolic function. Catheter Cardiovasc Interv 75: 586-93. Link: https://goo.gl/T7kVor
Cho Y-K, Shin H-W, Kinm H-T, Kim I-C, Park H-S, et al. (2009) Percutaeous coronary intervention in patients with severe left ventricular dysfunction. Am J Cardiol 103: 55.
Naidu SS, Faith S, Vlachos H, Holper E, Wilensky RL, et al. (2009) Safety of drug eluting stents in patients with severe left ventricular dysfunction: one year data from the NHLBI dynamic registry. J Am Coll Cardiol 53: A76.
Marsico F, Morenghi E, Parenti DZ, Milone F, Maiello L, et al. (2003) Immediate and late results of coronary angioplasty in patients with severe left ventricular dysfunction. Ital Heart J 4: 838–842.
Li C, Jia G, Guo W, Li W (2002) Stent supported coronary angioplasty in patients with severe ventricular dysfunction. Chin Med J (Engl) 115: 355–358. Link: https://goo.gl/nB5cLQ
Bukachi F, Clague JR, Waldenstrom A, Kazzam E, Henein MY (2003) Clinical outcome of coronary angioplasty in patients with ischaemic cardiomyopathy.Int J Cardiol 88: 167–174.
Lipinski MJ, Martin RE, Cowley MJ, Goudreau E, Malloy WN, et al. (2005) Improved survival for stenting vs. balloon angioplasty for the treatment of coronary artery disease in patients with ischemic left ventricular dysfunction.Catheter Cardiovasc Interv 66: 547–553. Link: https://goo.gl/w2AnrA
Nusca A, Lipinski MJ, Varma A, Appleton DL, Goudreau E, et al. (2008) Safety of drug-eluting stents in patients with left ventricular dysfunction undergoing percutaneous coronary intervention. Am J Cardiol 102: 679-82.
Holper EM, Blair J, Selzer F, Detre KM, Jacobs AK, et al. (2006) Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry Investigators. The impact of ejection fraction on outcomes after percutaneous coronary intervention in patients with congestive heart failure: an analysis of the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry. Am Heart J 151: 69-75. Link: https://goo.gl/oj65wy
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, et al. (2011) Coronary-artery bypass surgery in patients with left ventricular dysfunction.
N Engl J Med 364: 1607–1616. Link: https://goo.gl/Azf5Zu
Kunadian V, Zaman A, Qiu W (2011) Revascularization among patients with severe left ventricular dysfunction: a meta-analysis of observational studies. Eur J Heart Fail 13: 773–784. Link: https://goo.gl/wWFipQ
Hawranek M, Zembala MO, Gasior M (2018) Comparison of coronary artery bypass grafting and percutaneous coronary intervention in patients with heart failure with reduced ejection fraction and multivessel coronary artery disease. Oncotarget 9: 21201-21210. Link: https://goo.gl/eXBpPe
Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL (2016) Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. Circulation 133: 2132-2140.
Jiang L, Xu L, Song L, Gao Z, Tian J, et al. (2018) Comparison of three treatment strategies for patients with triple-vessel coronary disease and left ventricular dysfunction. J Interv Cardiol 31: 310-318. Link: https://goo.gl/yKqxT7
Cui K, Zhang D, Lyu S, Song X, Yuan F, et al. (2018) Meta-Analysis Comparing Percutaneous Coronary Revascularization Using Drug-Eluting Stent Versus Coronary Artery Bypass Grafting in Patients With Left Ventricular Systolic Dysfunction. Am J Cardiol S0002-9149(18)31628-X. Link: https://goo.gl/cPRvtW
Luciani GB, Montalbano G, Casali G, Mazzucco A (2000) Predicting long-term functional results after myocardial revascularization in ischemic cardiomyopathy. J Thorac Cardiovasc Surg 120: 478–89. Link: https://goo.gl/UA9uJe
Bourassa MG, Kip KE, Jacobs AK (1999) Is a strategy of intended incomplete percutaneous transluminal coronary angioplasty revascularization acceptable in nondiabetic patients who are candidates for coronary artery bypass graft surgery? J Am Coll Cardiol 33: 1627–36. Link: https://goo.gl/mP9gvq
Wolff G, Dimitroulis D, Andreotti F (2017) Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis. Circ Heart Fail 10: e003255.
Stefanini GG, Holmes DR Jr (2013) Drug-eluting coronary-artery stents. N Engl J Med 368: 254–265. Link:
Hannan EL, Wu C, Walford G, Holmes DR, Jones RH, et al. (2009) Incomplete revascularization in the era of drug-eluting stents:impact on adverse outcomes. JACC Cardiovasc Interv 2: 17-25. Link: https://goo.gl/PezLM6
Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, et al. (2007) Five-year follow-up of the Medicine, Angioplasty,or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115: 1082-9.